Axial Spondyloarthritis
Clinicians accept own opinion of low disease activity over T2T in axial spondyloarthritis
In patients with residual axial spondyloarthritis disease activity, many physicians avoid strict adherence to treat-to-target guidelines in favor of low disease activity, based on their own opinion, as a treatment goal, according to data.
Lack of ‘good disease model’ inhibits treatment decision-making in axial spondyloarthritis
DESTIN, Fla. — Incomplete understanding of axial spondyloarthritis disease process poses challenges for treatment decision making, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Glucocorticoid use, male sex predict more severe COVID-19 in psoriatic disease, axial SpA
Glucocorticoid use, older age, male sex and comorbidity burden are among the predictors of more severe COVID-19 in patients with psoriasis, psoriatic arthritis or axial spondyloarthritis, according to data.
Ixekizumab demonstrates no new safety concerns over 3 years in axial spondyloarthritis
An analysis of long-term ixekizumab use over 3 years in patients with axial spondyloarthritis found no new safety signals, according to data published in The Journal of Rheumatology.
Postpartum patients may be at risk for false-positive axial spondyloarthritis diagnosis
As many as 41% of patients who are 1 year postpartum meet the ASAS criteria for sacroiliitis, which could lead to false positive diagnoses of axial spondyloarthritis, according to data published in Arthritis & Rheumatology.
‘A little bit unique’: Consider every SAPHO manifestation when examining patients
SCOTTSDALE, Ariz. — SAPHO is complex, but knowing its potential manifestations can help clinicians identify and help patients, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician meeting.
One-quarter of patients with axial SpA remain flare-free after ceasing etanercept
In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data published in the Journal of Rheumatology.
Bimekizumab achieves significant, rapid improvements in axial spondyloarthritis
The use of bimekizumab to inhibit both interleukin-17A and IL-17F was well-tolerated and impactful in improving axial spondyloarthritis outcomes across two phase 3 trials, according to data published in the Annals of the Rheumatic Diseases.
Celecoxib added to golimumab fails to slow spine damage vs monotherapy in axial SpA
PHILADELPHIA — Combination therapy with celecoxib plus golimumab failed to show significant superiority to golimumab alone in slowing spine damage in radiographic axial spondyloarthritis, according to data presented at ACR Convergence 2022.
Treatment retention ‘high’ after infliximab biosimilar-to-biosimilar switch
PHILADELPHIA — Patients who switched from one infliximab biosimilar to another experienced comparable treatment retention rates, according to data presented at ACR Convergence 2022.